Annals of Urologic Oncology

Submit Manuscript

Table of Contents

  • Using Artificial Intelligence to Advance Renal Cancer Diagnosis, Treatment, and Precision Medicine

    Darragh Walsh, Callum Hayes

    Renal cancer (RC) ranks tenth among the most frequently diagnosed cancers and affects both men and women worldwide. This disease is a significant global health issue, highlighting the need for accurate and rapid diagnostic tools to guide treatment. Conventional pathological methods have drawbacks, such as extended evaluation procedures and inter-observer inconsistency. Recent developments in artif...

    REVIEW | Published: 02 Sep 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 2

    Pages: 59-67   PDF(2240KB)   Views:190Downloads:3

  • The Concomitant Use of Angiotensin System Inhibitors Predicts Favorable Prognosis for Renal Cell Carcinoma Patients

    Shuenqin Hu, Xiuying Li

    Previous data suggest that Angiotensin system inhibitors (ASIs) may exert antitumor effects; however, the findings remain controversial. Therefore, the present study was conducted to evaluate the association between concomitant use of ASIs and survival outcomes in patients with renal cell carcinoma (RCC)....

    REVIEW | Published: 28 Aug 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 2

    Pages: 68-75   PDF(1020KB)   Views:225Downloads:5

  • Metabolic Reprogramming in Kidney Cancer: Implications for Therapy

    Elena Tena Edo

    Kidney cancer, particularly clear cell renal cell carcinoma (ccRCC), has emerged as a paradigm for cancer metabolic reprogramming, exhibiting distinctive alterations that drive tumor progression and therapeutic resistance. This comprehensive review synthesizes current knowledge of the molecular mechanisms underlying metabolic dysregulation in kidney cancer, with emphasis on the central role of VHL...

    REVIEW | Published: 07 Aug 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 2

    Pages: 76-87   PDF(1290KB)   Views:550Downloads:3

  • Synthetic Lethality in Prostate Cancer: Evaluating the Role of PARP Inhibitors in BRCA-Mutated mCRPC

    Xinliang Xu, Minna Liu

    Prostate cancer, a leading cause of cancer-related mortality in men, often progresses to metastatic castration-resistant prostate cancer (mCRPC) despite advances in treatment with androgen-receptor pathway inhibitors (ARPIs) and taxanes. Recent genomic studies have highlighted that alterations in DNA damage repair genes, notably BRCA1 and BRCA2, play a significant role in the progression of prosta...

    REVIEW | Published: 23 Jul 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 2

    Pages: 88-96   PDF(1310KB)   Views:961Downloads:7

  • Saliva-Based Polygenic Risk Scores and AI-Enhanced Imaging for Prostate Cancer Screening beyond PSA

    Fan Li, Xian Zhang

    Prostate-specific antigen (PSA) testing, long used for prostate cancer screening, is limited by poor specificity (~25%), leading to unnecessary biopsies in over 70% of cases and substantial healthcare costs. This review synthesizes recent evidence (2023–2025) on emerging non-invasive diagnostics—saliva-based polygenic risk scores (PRS) and artificial intelligence (AI)-enhanced ...

    REVIEW | Published: 31 Jul 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 2

    Pages: 97-105   PDF(629KB)   Views:898Downloads:4

  • The Urological Subtleties of an Uncommon Encounter with Primary Mucinous Adenocarcinoma of the Urinary Bladder with Review of Literature

    Anuradha Pandit, Shaivy Malik ... Charanjeet Ahluwalia

    Primary mucinous adenocarcinoma (PMA) of the urinary bladder is a rare and aggressive neoplasm, accounting for 0.5-2% of bladder malignancies. We report a case of a 52-year-old male presenting with urinary obstructive symptoms and hematuria. Imaging revealed a bladder mass, and histopathology confirmed muscle-invasive mucinous adenocarcinoma with characteristic mucin pools and signet ring cells. I...

    CASE REPORT | Published: 07 Aug 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 2

    Pages: 106-115   PDF(1810KB)   Views:332Downloads:4

  • Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer

    Beatriz Ramos, Dakota Rogers

    Bladder cancer is among most common malignancies worldwide, with significant morbidity and mortality. Conventional treatment strategies for bladder cancer include transurethral resection, radical cystectomy and chemotherapy. However, the complex immune landscape of bladder cancer involves innate and adaptive immune components that either promote or suppress tumor progression. Upregulation of check...

    REVIEW | Published: 05 Feb 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 1

    Pages: 1-11   PDF(1670KB)   Views:1517Downloads:20

  • Advancements in Research on Non-AR- Signaling Pathways and Targeted Therapies for Castration-Resistant Prostate Cancer

    Haq Dad, Asger Hansen

    Prostate cancer (Pca) is a significant malignancy affecting men's health, with its incidence steadily increasing worldwide in recent years. Among its various subtypes, castration-resistant prostate cancer (CRPC) holds particular importance due to its pivotal role in the progression and management of Pca. The treatment options for Pca range from surgery to medication. However, the mechanisms underl...

    REVIEW | Published: 27 Dec 2024

    Annals of Urologic Oncology, Volume 8 (2025), Issue 1

    Pages: 12-20   PDF(1200KB)   Views:1790Downloads:16

  • Advances in Illuminating Prostate Cancer with Emerging Phototherapies

    Ali Usman

    Prostate cancer is a worldwide health concern in men, with substantially high incidence rate and advanced metastatic disease-related mortality rates. Despite advancements in diagnostics and treatment options, conventional therapies for prostate cancer, including surgery, radiotherapy, chemotherapy and androgen deprivation therapy, face limitations such as treatment resistance, limited precision an...

    REVIEW | Published: 31 Jan 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 1

    Pages: 21-29   PDF(2220KB)   Views:2988Downloads:16

  • A Potential Role of MicroRNA in the Renal Cancer and Its Tumor Microenvironment

    Daniel Chikere Ali, Siva Bharath Merugu

    Renal cell carcinoma (RCC) accounts for approximately 2.2% of all diagnosed cancers and 1.8% of cancer-related deaths. Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of RCC, accounting for approximately 70–80% of all cases. Despite significant advancements in therapeutic strategies over recent decades, treatment outcomes for ccRCC patients remain suboptimal. Prognosis for in...

    REVIEW | Published: 29 Jan 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 1

    Pages: 30-39   PDF(1930KB)   Views:1580Downloads:9

  • Metabolic Supremacy Fuels Tumor Aggressiveness in Renal Cancer

    Reham Gholam, Muhammad Khalilzad

    Renal cell carcinoma, with clear cell renal carcinoma (ccRCC) being the dominant form, is recognized as a malignancy driven by abnormal metabolic processes, with extensive alterations in glucose, lipid, and amino acid pathways. The loss of the Von Hippel-Lindau (VHL) gene in nearly 90% of ccRCC instances results in the accumulation of hypoxia-inducible factors (HIFs), producing a pseudo-hypoxic en...

    REVIEW | Published: 02 Mar 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 1

    Pages: 40-49   PDF(1910KB)   Views:1404Downloads:8

  • Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication

    Ghulam Raza, Kareem Khan

    Renal cell carcinoma (RCC) is the common type of kidney cancer linked to alteration of lipid, glucose, and amino acid metabolism. Early stage RCC has prognosis with overall 5-year survival rate of 90%, and the RCC has unfavorable prognosis when the disease metastasizes. Loss of or carrying mutated tumor suppressor gene VHL is the cause of HIF elevation leading to initiation of RCC. The epidermal g...

    REVIEW | Published: 23 Mar 2025

    Annals of Urologic Oncology, Volume 8 (2025), Issue 1

    Pages: 50-58   PDF(1125KB)   Views:1306Downloads:9